Volume 55, Issue 2, Pages (August 2011)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 61, Issue 2, Pages (August 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Volume 66, Issue 3, Pages (March 2017)
Inflammasomes in liver diseases
New Diagnostic Criteria and Management of Acute Kidney Injury
MELD: the holy grail of organ allocation?
Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure  Patricia Huelin,
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
m-TOR inhibitors: What role in liver transplantation?
From: Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate.
Fig. 1. Distribution of eGFR according to baseline SCr
Volume 62, Issue 4, Pages (April 2015)
m-TOR inhibitors: What role in liver transplantation?
Volume 68, Issue 5, Pages (May 2018)
Ascites and Hepatorenal Syndrome: Pathophysiology and Management
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
The impact of hepatitis E in the liver transplant setting
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Pulmonary contraindications, indications and MELD exceptions for liver transplantation: A contemporary view and look forward  Michael J. Krowka, Russell.
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Marcus-Alexander Wörns, Peter Robert Galle  Journal of Hepatology 
Living donor liver transplantation: is the hype over?
Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure  Patricia Huelin,
Reply to: “DCD consensus and futility in liver transplantation”
The place of downstaging for hepatocellular carcinoma
Volume 58, Issue 3, Pages (March 2013)
Mauro Bernardi, Stefano Gitto, Maurizio Biselli  Journal of Hepatology 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Familial amyloid polyneuropathy and liver transplantation
Hepatitis C core protein – The “core” of immune deception?
Vicente Arroyo, Carlos Terra, Pere Ginès  Journal of Hepatology 
Masaru Horio  American Journal of Kidney Diseases 
Volume 62, Issue 3, Pages (March 2015)
Management of cirrhosis due to chronic hepatitis C
Volume 134, Issue 5, Pages (May 2008)
Erratum American Journal of Kidney Diseases
Andres Cardenas, Pere Ginès  Journal of Hepatology 
Volume 66, Issue 2, Pages (February 2017)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Age and liver transplantation
The Modification of Diet in Renal Disease 4-calculated glomerular filtration rate is a better prognostic factor of cardiovascular events than classical.
Issue Highlights Clinical Gastroenterology and Hepatology
Volume 65, Issue 2, Pages (August 2016)
Quiz Page July 2012 American Journal of Kidney Diseases
Volume 53, Issue 6, Pages (December 2010)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Immunosuppression in liver transplant recipients with renal impairment
Immigration and viral hepatitis
HCV targeting of patients with cirrhosis
Volume 76, Issue 3, Pages (August 2009)
Drug Dose Adjustments in Patients With Renal Impairment
Volume 63, Issue 1, Pages (July 2015)
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
m-TOR inhibitors: What role in liver transplantation?
New trials and results in systemic treatment of HCC
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Volume 80, Issue 10, Pages (November 2011)
Genetics of hepatocellular carcinoma: The next generation
MELD: the holy grail of organ allocation?
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Managing the Complications of Cirrhosis
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 55, Issue 2, Pages 491-496 (August 2011) Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation?  Salvatore Piano, Filippo Morando, Silvano Fasolato, Marta Cavallin, Novella Boscato, Patrizia Boccagni, Giacomo Zanus, Umberto Cillo, Angelo Gatta, Paolo Angeli  Journal of Hepatology  Volume 55, Issue 2, Pages 491-496 (August 2011) DOI: 10.1016/j.jhep.2011.02.002 Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Time course of serum creatinine and treatment with terlipressin and albumin in patient 1. The daily dose of terlipressin is also indicated. Albumin was administered at the dose of 20–40g/day for the duration of treatment with terlipressin. Dotted line indicates a 133μmol/L value of serum creatinine. Dashed line indicates a 226μmol/l value of serum creatinine. Journal of Hepatology 2011 55, 491-496DOI: (10.1016/j.jhep.2011.02.002) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Model of End Stage Liver Disease (MELD) score, Na-MELD. ‘Actual’ values were calculated on the basis of the serum creatinine value during treatment. ‘Real’ values were calculated on the basis of the peak value of serum creatinine during the last episode of type 1 HRS. Journal of Hepatology 2011 55, 491-496DOI: (10.1016/j.jhep.2011.02.002) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Time course of glomerular filtration rate calculated on the basis of the Modification of Diet in Renal Disease (MDRD) equation after LT in the three patients. Journal of Hepatology 2011 55, 491-496DOI: (10.1016/j.jhep.2011.02.002) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Time course of serum creatinine and treatment with terlipressin and albumin in patient 2. The daily dose of terlipressin is also indicated. Albumin was administered at the dose of 20–40g/day for the duration of treatment with terlipressin. Dotted line indicates a 133μmol/L value of serum creatinine. Dashed line indicates a 226μmol/L value of serum creatinine. Journal of Hepatology 2011 55, 491-496DOI: (10.1016/j.jhep.2011.02.002) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 5 Time course of serum creatinine and treatment with terlipressin and albumin in patient 3. The dose of terlipressin is also indicated. Albumin was administered at the dose of 20–40g/day for the duration of treatment with terlipressin. Dotted line indicates a 133μmol/L value of serum creatinine. Dashed line indicates a 226μmol/L value of serum creatinine. Journal of Hepatology 2011 55, 491-496DOI: (10.1016/j.jhep.2011.02.002) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions